Jason Cohen, Editor

About the Author Jason Cohen, Editor


Cantor Bets on Opko Health Inc. (OPK); Sees 240% Upside

Looking for a reason to buy shares of Opko Health Inc. (NASDAQ:OPK)? How about three …

Read more

Cantor Shines Light on TherapeuticsMD Inc (TXMD) Following Publication of Clinical Data in Menopause

Cantor analyst William Tanner is out today with a few insights on TherapeuticsMD Inc (NYSEMKT:TXMD), after the …

Read more

Adamas Pharmaceuticals Inc (ADMS) Shares Slip Ahead of PDUFA Date; Mizuho More Cautious

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) saw its shares slipping nearly 17% this month ahead of the …

Read more

Cowen Dives In on ACADIA Pharmaceuticals Inc. (ACAD) Following Meeting with Management

Cowen analyst Ritu Baral has recently attended a meeting with ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) management to discuss the …

Read more

Maxim Sees Over 200% Upside for MannKind Corporation (MNKD)

  Shares of MannKind Corporation (NASDAQ:MNKD) are up nearly 3% in Friday trading session, as …

Read more

Two Interesting Biotech Stocks with Upcoming Catalysts: Kamada Ltd. (KMDA), Dynavax Technologies (DVAX)

Kamada: Jefferies Sees 60% Upside for the Stock Kamada Ltd (NASDAQ:KMDA) has an upcoming PDUFA …

Read more

What You Need To Know About Galena Biopharma Inc (GALE) Merger With SELLAS; Maxim Shines Light

Yesterday, Galena Biopharma Inc (NASDAQ:GALE) and SELLAS Life Sciences announced they have entered into an …

Read more

What Analysts Are Saying About Biotech Stocks Achillion Pharmaceuticals, Inc. And ACADIA Pharmaceuticals Inc.

Achillion Pharmaceuticals, Inc. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares are rising about 25% in Wednesday’s trading …

Read more

Healthcare Analysts Change Price Targets on Myokardia Inc (MYOKׂ) and Zynerba Pharmaceuticals Inc (ZYNE) Following Clinical Readouts

Healthcare analysts expressed their opinions on Myokardia Inc (NASDAQ:MYOK) and Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) after …

Read more

Cowen Raises Red Flag on AcelRx Pharmaceuticals Inc (ACRX) Ahead of Dsuvia’s PDUFA

The next key catalyst for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Dsuvia’s Prescription Drug User Fee …

Read more